About Us

Dr. David P. Schleimer is Board Certified in Otolaryngology and Facial Plastic Surgery and has been in private practice since 2016. Dr. Schleimer’s practice takes a special interest in working with his patients to achieve a common goal in treatment of ear, nose and throat complaints. After receiving his Bachelor of Science in Microbiology from The Ohio State University, Dr. Schleimer began his quest to treat human disease by performing basic science research investigating pediatric blood cancers at Cincinnati Children’s Hospital Medical Center. Inspired by graduate courses in human development and otolaryngologic disorders, Dr. Schleimer elected to pursue his medical degree from the Ohio University Heritage College of Osteopathic Medicine. Further training in Otolaryngology and Facial Plastic Surgery brought Dr. Schleimer to the greater Detroit area when he matched to the St. John-Providence residency program credentialed through Michigan State University. Seeing patients of all ages with ear, nose and throat illnesses motivates Dr. Schleimer to stay up to date on current medical and surgical options to return his patients to optimal health. Dr. Schleimer and his family reside in southeast Michigan where they enjoy the outdoors year-round, explore local restaurants, and stay involved in the community.

Society Memberships:

American Academy of Otolaryngology-Head and Neck Surgery, American Osteopathic College of Ophthalmology and Otolaryngology-Head and Neck Surgery, American Osteopathic Association, Michigan Osteopathic Association, American Rhinologic Society.

Awards:

First Place: Otolaryngology Resident Research Poster Competition At 100th Annual Clinical Assembly; “Voice and Breathing Outcomes with Current Reinke’s Edema Treatment”.

Peer Reviewed Publications:

Moehrle BM, Nattamai K, Brown A, Florian MC, Ryan M, Vogel M, Bliederhaeuser C, Soller K, Prows DR, Abdollahi A, Schleimer D, Walter D, Milsom MD, Stambrook P, Porteus M, Geiger H. Stem Cell-Specific Mechanisms Ensure Genomic Fidelity within HSCs and upon Aging of HSCs. Cell Rep. 2015 Dec 22;13(11):2412-2424.

Ryan MA, Nattamai KJ, Xing E, Schleimer D, Daria D, Sengupta A, Köhler A, Liu W, Gunzer M, Jansen M, Ratner N, Le Cras TD, Waterstrat A, Van Zant G, Cancelas JA, Zheng Y, Geiger H. Pharmacological inhibition of EGFR signaling enhances G-CSF-induced hematopoietic stem cell mobilization. Nat Med. 2010 Oct;16(10):1141-6.

Geiger H, David S, Nattamai KJ, Jan V. Quantification of genomic mutations in murine hematopoietic cells. Methods Mol Biol. 2009;506:423-36.

Milsom MD, Jerabek-Willemsen M, Harris CE, Schambach A, Broun E, Bailey J, Jansen M, Schleimer D, Nattamai K, Wilhelm J, Watson A, Geiger H, Margison GP, Moritz T, Baum C, Thomale J, Williams DA. Reciprocal relationship between O6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cells. Cancer Res. 2008 Aug 1;68(15):6171-80.

Krejci O, Wunderlich M, Geiger H, Chou FS, Schleimer D, Jansen M, Andreassen PR, Mulloy JC. p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death. Blood. 2008 Feb 15;111(4):2190-9.

Geiger H, Schleimer D, Nattamai KJ, Dannenmann SR, Davies SM, Weiss BD. Mutagenic potential of temozolomide in bone marrow cells in vivo. Blood. 2006 Apr 1;107(7):3010-1.